Readership
Biomedical Researchers, Cell Biologists, Clinical Pharmacologists, Clinicians, Endocrinologists, Epidemiologists, Health Scientists, Immunologists, Molecular Biologists, Nuclear Medicine Physicians, Oncologists, Pathologists, Pharmaco-Epidemiologists, Pharmacologists, Physicians, Physicians - Medicine, Radiation Oncologists, Scientists, Surgical Oncologists
Scope
Molecular Oncology is a monthly online-only Open Access journal that highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational cancer research.
The emphasis is on work that significantly advances our understanding of disease processes leading to human tumour development and/or establishes novel concepts of clear clinical significance in diagnosis, prognosis and prevention strategies for cancer patients. Submissions that meet the high standards of the journal are sent for rigorous, single-blind peer review by experts in the field.
Topics include, but are not limited to:
Key biological processes such as cell cycle; DNA repair; apoptosis; invasion and metastasis; angiogenesis and lymphangiogenesis; cell signalling and interactive networks; immune response.
Emerging technologies (genomics, proteomics, functional genomics, metabolomics, tissue arrays, imaging), and model systems.
Biomarkers: diagnosis, prognosis, stratification and efficacy.
Cancer genetics, epigenetics, and genomic instability.
Minimal residual disease, pre-malignant lesions.
Cancer micro-environment.
Molecular pathology.
Tumour immunology.
Translational research.
Cancer therapy (target discovery, drug design, immunotherapy, combination therapies, resistance, and individualised treatment).
Chemotherapy, radiotherapy and surgery.
Clinical pharmacology.
Clinical trials, integration of basic science into cancer clinical trials.
Molecular epidemiology.